CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Vertex Pharmaceuticals' shares have soared 24% year to date despite the macroeconomic headwinds in its way. The biotech owes that in part to its dominance in the market for drugs that treat the underlying causes of cystic fibrosis (CF), an area in which Vertex is the only game in town. Revenue and earnings continue to grow for Vertex thanks to its CF franchise.
An estimates-beating quarter and raised guidance were the elements pushing Vertex Pharmaceuticals (NASDAQ: VRTX) shares comfortably higher on Friday. After market hours on Thursday, Vertex published its second-quarter results. Vertex's growth was powered by its current blockbuster drug, Trikafta.